​

Kiniksa Pharmaceuticals (KNSA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KNSA Stock Forecast

Kiniksa Pharmaceuticals (KNSA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $51.00, with a high of $55.00 and a low of $44.00. This represents a 29.34% increase from the last price of $39.43.

$15 $23 $31 $39 $47 $55 High: $55 Avg: $51 Low: $44 Last Closed Price: $39.43

KNSA Stock Rating

Kiniksa Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

KNSA Price Target Upside V Benchmarks

TypeNameUpside
StockKiniksa Pharmaceuticals29.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts234
Avg Price Target$49.50$51.00$47.00
Last Closing Price$39.43$39.43$39.43
Upside/Downside25.54%29.34%19.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2516---7
Sep, 2515---6
Aug, 2515---6
Jul, 2524---6
Jun, 2524---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2025Goldman Sachs$55.00$37.8145.46%39.49%
Oct 13, 2025Wedbush$44.00$37.8916.13%11.59%
Jul 29, 2025Jefferies$54.00$30.3777.81%36.95%
Oct 29, 2024Liisa BaykoEvercore ISI$35.00$23.2750.41%-11.24%
Sep 13, 2024Roger SongJefferies$40.00$24.4963.33%1.45%
May 03, 2024Eva Fortea VerdejoWells Fargo$34.00$19.3875.44%-13.77%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2025Goldman SachsBuyBuyhold
Oct 22, 2025Cowen & Co.BuyBuyhold
Oct 17, 2025CitigroupBuyBuyhold
Oct 13, 2025WedbushOutperformOutperformhold
Sep 29, 2025Cowen & Co.Buyinitialise
Oct 29, 2024Evercore ISIOutperformOutperformhold
Sep 13, 2024JefferiesBuyinitialise
Jul 24, 2024Wells FargoOverweightOverweighthold
May 03, 2024Wells FargoOverweightinitialise

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.30$2.64$0.20$-0.60----
Avg Forecast$-2.18$2.38$-0.17$-0.39$0.56$0.83$1.45$0.77
High Forecast$-2.13$2.48$-0.15$-0.29$1.26$1.24$1.91$0.81
Low Forecast$-2.29$2.31$-0.19$-0.43$0.05$0.47$1.12$0.74
Surprise %5.50%10.92%-217.65%53.85%----

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$38.54M$220.18M$270.26M$423.24M----
Avg Forecast$37.40M$203.34M$260.12M$424.18M$578.12M$683.58M$802.31M$845.00M
High Forecast$38.77M$210.11M$260.98M$424.42M$584.28M$708.11M$803.74M$875.33M
Low Forecast$36.65M$198.96M$259.26M$423.70M$569.27M$664.88M$800.88M$821.89M
Surprise %3.06%8.28%3.90%-0.22%----

Net Income Forecast

$-200M $-120M $-40M $40M $120M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-157.92M$183.36M$14.08M$-43.19M----
Avg Forecast$-163.10M$-141.18M$14.08M$-25.95M$33.35M$55.73M$87.68M$55.38M
High Forecast$-130.48M$-112.94M$16.90M$-21.16M$90.76M$89.02M$137.72M$57.96M
Low Forecast$-195.71M$-169.41M$11.27M$-30.73M$3.24M$34.11M$80.34M$53.41M
Surprise %-3.17%-229.88%-66.46%----

KNSA Forecast FAQ

Is Kiniksa Pharmaceuticals stock a buy?

Kiniksa Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kiniksa Pharmaceuticals is a favorable investment for most analysts.

What is Kiniksa Pharmaceuticals's price target?

Kiniksa Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $51 over the next 12 months. The price target range spans from $44 at the low end to $55 at the high end, suggesting a potential 29.34% change from the previous closing price of $39.43.

How does Kiniksa Pharmaceuticals stock forecast compare to its benchmarks?

Kiniksa Pharmaceuticals's stock forecast shows a 29.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Kiniksa Pharmaceuticals over the past three months?

  • October 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Kiniksa Pharmaceuticals’s EPS forecast?

Kiniksa Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.56, marking a -193.33% decrease from the reported $-0.6 in 2024. Estimates for the following years are $0.83 in 2026, $1.45 in 2027, and $0.77 in 2028.

What is Kiniksa Pharmaceuticals’s revenue forecast?

Kiniksa Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $578.12M, reflecting a 36.60% increase from the reported $423.24M in 2024. The forecast for 2026 is $683.58M, followed by $802.31M for 2027, and $845M for 2028.

What is Kiniksa Pharmaceuticals’s net income forecast?

Kiniksa Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $33.35M, representing a -177.21% decrease from the reported $-43.193M in 2024. Projections indicate $55.73M in 2026, $87.68M in 2027, and $55.38M in 2028.